Related references
Note: Only part of the references are listed.NRAS mutation status is an independent prognostic factor in metastatic melanoma
John A. Jakob et al.
CANCER (2012)
Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab
Vafa Shahabi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
Fei Su et al.
CANCER RESEARCH (2012)
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
James S. Duncan et al.
CELL (2012)
The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
Kim H. T. Paraiso et al.
CLINICAL CANCER RESEARCH (2012)
RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors
Yingjun Su et al.
CLINICAL CANCER RESEARCH (2012)
Raf Inhibitors Target Ras Spatiotemporal Dynamics
Kwang-jin Cho et al.
CURRENT BIOLOGY (2012)
METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAFV600/k mutant advanced or metastatic melanoma (MM)
Caroline Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
Patrick A. Oberholzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition
Lisa Zimmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma
Richard W. Joseph et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition
Kavitha Gowrishankar et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Activated Mutant NRasQ61K Drives Aberrant Melanocyte Signaling, Survival, and Invasiveness via a Rac1-Dependent Mechanism
Ang Li et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
James G. Greger et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Sox 10 promotes the formation and maintenance of giant congenital naevi and melanoma
Olga Shakhova et al.
NATURE CELL BIOLOGY (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer
Sarat Chandarlapaty
CANCER DISCOVERY (2012)
Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
Inna V. Fedorenko et al.
BIOCHEMICAL PHARMACOLOGY (2011)
PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
Kim H. T. Paraiso et al.
CANCER RESEARCH (2011)
Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma
Julie A. Ellerhorst et al.
CLINICAL CANCER RESEARCH (2011)
GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
Aidan G. Gilmartin et al.
CLINICAL CANCER RESEARCH (2011)
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
Hiromichi Ebi et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
The Farnesyl Transferase Inhibitor Lonafarnib Inhibits mTOR Signaling and Enforces Sorafenib-Induced Apoptosis in Melanoma Cells
Heike Niessner et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
Human Cutaneous Melanomas Lacking MITF and Melanocyte Differentiation Antigens Express a Functional Axl Receptor Kinase
Marialuisa Sensi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
Kathryn Tworkoski et al.
MOLECULAR CANCER RESEARCH (2011)
ERK and PDE4 cooperate to induce RAF isoform switching in melanoma
Amelie Marquette et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R
Kerrington R. Molhoek et al.
MELANOMA RESEARCH (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells
F. M. Kaplan et al.
ONCOGENE (2011)
Meeting report from the 2011 international melanoma congress, Tampa, Florida
Keiran S. M. Smalley et al.
Pigment Cell & Melanoma Research (2011)
Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma
Bianca Devitt et al.
PIGMENT CELL & MELANOMA RESEARCH (2011)
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
Mohammad Atefi et al.
PLOS ONE (2011)
Targeted therapies of gastrointestinal stromal tumors (GIST)-The next frontiers
Stefan Duensing et al.
BIOCHEMICAL PHARMACOLOGY (2010)
4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors
Qing-Bai She et al.
CANCER CELL (2010)
A Mouse Model of Melanoma Driven by Oncogenic KRAS
Carla Milagre et al.
CANCER RESEARCH (2010)
Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells
Y. N. Vashisht Gopal et al.
CANCER RESEARCH (2010)
Akt3-Mediated Resistance to Apoptosis in B-RAF-Targeted Melanoma Cells
Yongping Shao et al.
CANCER RESEARCH (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
High Frequency of p16 INK4A Promoter Methylation in NRAS-Mutated Cutaneous Melanoma
Anders Jonsson et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Coexisting NRAS and BRAF Mutations in Primary Familial Melanomas with Specific CDKN2A Germline Alterations
Braslav Jovanovic et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling
Daniel A. Ritt et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation
P. J. Mishra et al.
ONCOGENE (2010)
Ral activation promotes melanomagenesis
P. A. Zipfel et al.
ONCOGENE (2010)
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma
Michael A. Davies et al.
CLINICAL CANCER RESEARCH (2009)
Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro
Malihe Eskandarpour et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
BrafV600E cooperates with Pten loss to induce metastatic melanoma
David Dankort et al.
NATURE GENETICS (2009)
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
K. S. M. Smalley et al.
ONCOGENE (2009)
The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma
SubbaRao V. Madhunapantula et al.
PIGMENT CELL & MELANOMA RESEARCH (2009)
Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors
Bijay S. Jaiswal et al.
PLOS ONE (2009)
A novel AKT3 mutation in melanoma tumours and cell lines
M. A. Davies et al.
BRITISH JOURNAL OF CANCER (2008)
Modeling genomic diversity and tumor dependency in malignant melanoma
William M. Lin et al.
CANCER RESEARCH (2008)
Akt and mutant V600EB-Raf cooperate to promote early melanoma development
Mitchefl Cheung et al.
CANCER RESEARCH (2008)
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel
Nikolas K. Haass et al.
CLINICAL CANCER RESEARCH (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
Alex A. Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
Mutant B-RAF mediates resistance to anoikis via Bad and Bim
K. Boisvert-Adamo et al.
ONCOGENE (2008)
Improving melanoma classification by integrating genetic and morphologic features
Amaya Viros et al.
PLOS MEDICINE (2008)
No evidence of RALGDS mutations in cutaneous melanoma
Katarina Omholt et al.
MELANOMA RESEARCH (2007)
Requirement for Rac1 in a K-ras-induced lung cancer in the mouse
Joseph L. Kissil et al.
CANCER RESEARCH (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Differential oncogenic potential of activated RAS isoforms in melanocytes
T. Whitwam et al.
ONCOGENE (2007)
Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets
Panagiotis A. Konstantinopoulos et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations
Juergen Bauer et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling
Nicolas Dumaz et al.
CANCER RESEARCH (2006)
Oncogene-induced cell senescence - Halting on the road to cancer
W. J. Mooi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma
M. Sensi et al.
ONCOGENE (2006)
BRAF mutation predicts sensitivity to MEK inhibition
DB Solit et al.
NATURE (2006)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells
QB She et al.
CANCER CELL (2005)
BRAFE600-associated senescence-like cell cycle arrest of human naevi
C Michaloglou et al.
NATURE (2005)
Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling
KV Bhatt et al.
ONCOGENE (2005)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma
H Tsao et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
FoxO3a transcriptional regulation of bim controls apoptosis in paclitaxel-treated breast cancer cell lines
A Sunters et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells
KSM Smalley et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?
KSM Smalley
INTERNATIONAL JOURNAL OF CANCER (2003)
High frequency of BRAF mutations in nevi
PM Pollock et al.
NATURE GENETICS (2003)
Targeting ras signalling pathways in cancer therapy
J Downward
NATURE REVIEWS CANCER (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms
N Dumaz et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Regulation of the forkhead transcription factor AFX by Ral-dependent phosphorylation of threonines 447 and 451
ND De Ruiter et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
GSK3 takes centre stage more than 20 years after its discovery
S Frame et al.
BIOCHEMICAL JOURNAL (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Dual inactivation of RB and p53 pathways in RAS-induced melanomas
N Bardeesy et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features
BC Bastian et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
